Dopamine quinones interact with alpha-synuclein to form unstructured adducts.
about
Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs)Cellular models to investigate biochemical pathways in Parkinson's diseaseDopamine-induced α-synuclein oligomers show self- and cross-propagation properties.Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's diseaseThe N-terminal residues 43 to 60 form the interface for dopamine mediated α-synuclein dimerisation.Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).Catecholamines and Neurodegeneration in Parkinson's Disease-From Diagnostic Marker to Aggregations of α-Synuclein.γ-Glutamylamines and neurodegenerative diseasesThe interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding.Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug?Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.The function of α-synuclein.Inhibition of amyloid oligomerization into different supramolecular architectures by small molecules: mechanistic insights and design rules.DT-diaphorase Protects Against Autophagy Induced by Aminochrome-Dependent Alpha-Synuclein Oligomers.Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson's Disease.A hyperbranched dopamine-containing PEG-based polymer for the inhibition of α-synuclein fibrillationCytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells.Commentary: Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?Oxidative stress and cellular pathologies in Parkinson's disease.α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.Guanidine hydrochloride denaturation of dopamine-induced α-synuclein oligomers: a small-angle X-ray scattering study.Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease.Stabilization of Alpha-Synuclein Oligomers In Vitro by the Neurotransmitters, Dopamine and Norepinephrine: The Effect of Oxidized Catecholamines.Superoxide dismutating molecules rescue the toxic effects of PINK1 and parkin loss.Oxidized DJ-1 Levels in Urine Samples as a Putative Biomarker for Parkinson's Disease.Tuning the Balance between Fibrillation and Oligomerization of α-Synuclein in the Presence of Dopamine
P2860
Q26823798-71DA1106-FEAA-48DA-9294-EB8F38E41806Q26829742-34B9C6FB-3CEB-4F41-A1C0-4C41F5B12D84Q30364908-EDB4CBB9-29EB-4101-970D-98462A470957Q34313803-6A1BDF45-7C99-48D5-B735-B0A1D2296D2CQ35094912-5A129C91-BEA4-4832-814D-3D06A3A08A28Q36282886-98E5ACDE-1B33-4DCF-94C3-13B72891B1C9Q36335146-7A579647-D00B-4A82-BEEE-1163BF2C3C14Q36377238-00915129-1DA8-4973-85D3-24A03CA958C8Q37246310-33426029-73EB-4BFA-888E-D1181DCFD3E2Q37886152-74686499-A414-42BF-8CE6-31D7C3276D04Q38085689-64486AC5-DEC7-4FF3-80C9-A720F5ED22E5Q38139561-7B7E3916-81B9-4D45-BEC9-F2F6780FC8ADQ38686092-E35DFB7D-3289-46B3-8A25-09CC7EABD09CQ38704492-20A8B6F4-781E-4D82-8C1D-468F5E058483Q38722255-284102CE-1A12-44F3-8DC5-61120026E946Q42055565-6A2090EE-933A-4219-BD84-B8F1918B6C65Q42124780-F8AF9900-5353-4CE4-9ED9-4C63492F1A5FQ42257009-852C22A7-84EC-42D8-93FB-462E1A945EB8Q46252606-6299404D-547F-435C-BD71-6F6CEBD20F8FQ48561683-C9F0100B-8108-43A9-AE91-E76CF4885691Q50939945-BF3362B1-2CF1-4943-8F34-8C90B0E4A1A8Q52373049-265488C7-64F7-4D3A-AF10-8CC62452BE61Q53512450-C1622AD9-BF09-49BB-B699-D7390313ED44Q55031519-9A700B6E-4756-4F11-96A4-81588C925B4AQ55259626-A3BBE7FA-1D57-4088-BF7F-1CCE58637205Q58580914-7907D17A-CB64-45B0-8653-CE17555F8707
P2860
Dopamine quinones interact with alpha-synuclein to form unstructured adducts.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Dopamine quinones interact with alpha-synuclein to form unstructured adducts.
@en
Dopamine quinones interact with alpha-synuclein to form unstructured adducts.
@nl
type
label
Dopamine quinones interact with alpha-synuclein to form unstructured adducts.
@en
Dopamine quinones interact with alpha-synuclein to form unstructured adducts.
@nl
prefLabel
Dopamine quinones interact with alpha-synuclein to form unstructured adducts.
@en
Dopamine quinones interact with alpha-synuclein to form unstructured adducts.
@nl
P2093
P50
P1476
Dopamine quinones interact with alpha-synuclein to form unstructured adducts
@en
P2093
Marco Bisaglia
Patrizia Polverino de Laureto
Stefano Mammi
P304
P356
10.1016/J.BBRC.2010.03.044
P407
P577
2010-03-10T00:00:00Z